MX343688B - Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. - Google Patents
Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.Info
- Publication number
- MX343688B MX343688B MX2013012923A MX2013012923A MX343688B MX 343688 B MX343688 B MX 343688B MX 2013012923 A MX2013012923 A MX 2013012923A MX 2013012923 A MX2013012923 A MX 2013012923A MX 343688 B MX343688 B MX 343688B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- making
- same
- sulfonamide compounds
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención provee compuestos sulfonamida tricíclicos y su uso en el tratamiento de trastornos médicos, tales como obesidad; se proveen composiciones farmacéuticas y métodos para hacer diversos compuestos tricíclicos; se contempla que los compuestos tengan actividad contra la metionil aminopeptidasa 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483275P | 2011-05-06 | 2011-05-06 | |
PCT/US2012/036793 WO2012154679A1 (en) | 2011-05-06 | 2012-05-07 | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013012923A MX2013012923A (es) | 2014-02-27 |
MX343688B true MX343688B (es) | 2016-11-16 |
Family
ID=46085253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013012923A MX343688B (es) | 2011-05-06 | 2012-05-07 | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. |
Country Status (10)
Country | Link |
---|---|
US (2) | US9242997B2 (es) |
EP (1) | EP2705035B1 (es) |
JP (1) | JP6035327B2 (es) |
KR (1) | KR20140040739A (es) |
CN (1) | CN103764652B (es) |
AU (1) | AU2012253760B2 (es) |
BR (1) | BR112013028666A2 (es) |
CA (1) | CA2835209A1 (es) |
MX (1) | MX343688B (es) |
WO (1) | WO2012154679A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
CN102791699B (zh) | 2010-01-08 | 2016-04-06 | 扎夫根公司 | 烟曲霉醇型化合物和其制造和使用方法 |
WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
BR112013001613A2 (pt) | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
JP5913333B2 (ja) | 2010-10-12 | 2016-04-27 | ザフゲン,インコーポレイテッド | スルホンアミド化合物、およびそれを製造し使用する方法 |
JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
KR20140006888A (ko) | 2011-01-26 | 2014-01-16 | 자프겐 인크. | 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법 |
JP5876513B2 (ja) | 2011-03-08 | 2016-03-02 | ザフゲン,インコーポレイテッド | オキサスピロ[2.5]オクタン誘導体および類似体 |
CA2835195A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
BR112013028534A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos |
JP6035327B2 (ja) | 2011-05-06 | 2016-11-30 | ザフゲン,インコーポレイテッド | 三環式ピラゾールスルホンアミド化合物ならびにその製造および使用方法 |
EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
CA2861381A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
KR20140112565A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
AU2013259617A1 (en) | 2012-05-08 | 2014-11-27 | Zafgen, Inc. | Treating hypothalamic obesity with MetAP2 inhibitors |
AU2013259620B2 (en) | 2012-05-09 | 2017-05-18 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
AU2013337287B2 (en) | 2012-11-05 | 2017-03-23 | Zafgen, Inc. | Methods of treating liver diseases |
CA2890344A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
WO2014071363A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
CN104592122B (zh) * | 2014-12-09 | 2018-01-23 | 凯莱英医药集团(天津)股份有限公司 | 3‑(4‑甲基‑1h‑咪唑‑1‑基)‑5‑(三氟甲基)苯胺的制备方法 |
CN107428695B (zh) * | 2015-04-09 | 2021-03-16 | 奥赖恩公司 | 用于制备雄激素受体拮抗剂及其中间体的方法 |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
ES2099064T3 (es) | 1988-09-01 | 1997-05-16 | Takeda Chemical Industries Ltd | Derivados de fumagillol. |
ATE87623T1 (de) | 1989-03-06 | 1993-04-15 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
TW282399B (es) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
JPH05107705A (ja) * | 1991-10-17 | 1993-04-30 | Konica Corp | 新規な写真用カプラー |
US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
EP0555693B1 (en) | 1992-01-30 | 2001-09-05 | Takeda Chemical Industries, Ltd. | Method of producing highly watersoluble cyclodextrin complex |
ATE153854T1 (de) | 1992-12-16 | 1997-06-15 | Takeda Chemical Industries Ltd | Stabile pharmazeutische zubereitung mit fumagillolderivaten |
CN1072485C (zh) | 1995-03-27 | 2001-10-10 | 萨诺费合成实验室 | 夫马菌醇及其衍生物用于制备抗肠道感染药物的用途 |
US6180626B1 (en) | 1995-10-11 | 2001-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Vascular-permeability suppressants |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
AU3968597A (en) | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
JP2001518081A (ja) | 1997-03-04 | 2001-10-09 | モンサント カンパニー | スルホニル2価アリールまたはヘテロアリールヒドロキサム酸化合物 |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
WO1999039702A2 (en) | 1997-10-31 | 1999-08-12 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
JP2001526255A (ja) | 1997-12-23 | 2001-12-18 | ワーナー−ランバート・カンパニー | 炎症性疾患およびアテローム性動脈硬化症を治療または予防するチオ尿素およびベンズアミド化合物、組成物並びに方法 |
US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
ES2261202T3 (es) | 1999-04-28 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de acido de triarilo como ligandos para el receptor ppar. |
EP1223932A4 (en) | 1999-10-01 | 2003-01-15 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
UY26929A1 (es) | 2000-09-29 | 2002-04-26 | Abbott Lab | Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
MXPA03003775A (es) | 2000-11-01 | 2003-07-28 | Praecis Pharm Inc | Peptidos como inhibidores de met-ap2. |
EE200300303A (et) | 2000-12-20 | 2003-12-15 | Bristol-Myers Squibb Company | Asendatud pürrolokinoliinid ja püridokinoliinid kui serotoniini agonistid ja antagonistid |
EP1379241A1 (en) | 2001-03-29 | 2004-01-14 | SmithKline Beecham Corporation | Compounds and methods |
US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
US7087768B2 (en) | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US20040068012A1 (en) | 2002-10-08 | 2004-04-08 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
EP1651622B1 (en) | 2003-08-08 | 2007-02-07 | Janssen Pharmaceutica N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
WO2005025554A2 (en) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Dipeptidyl peptidase iv inhibitor |
DE602004010299T2 (de) | 2003-12-22 | 2008-09-18 | Memory Pharmaceuticals Corp. | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen |
WO2005066197A2 (en) | 2003-12-29 | 2005-07-21 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
JP2007537275A (ja) | 2004-05-12 | 2007-12-20 | ケモセントリックス, インコーポレイテッド | アリールスルホンアミド |
WO2006004803A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
KR20070057252A (ko) | 2004-09-24 | 2007-06-04 | 얀센 파마슈티카 엔.브이. | 설폰아미드 화합물 |
CN101142210A (zh) | 2005-01-26 | 2008-03-12 | 株式会社钟根堂 | 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物 |
FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US20090325975A1 (en) * | 2005-07-15 | 2009-12-31 | Helmut H Buschmann | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
US7282588B2 (en) | 2005-12-23 | 2007-10-16 | Smithkline Beecham | Azaindole inhibitors of aurora kinases |
US20100234364A1 (en) | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
CN101932577B (zh) | 2007-11-30 | 2013-07-17 | 拜耳知识产权有限责任公司 | 杂芳基取代的哌啶 |
CN102123586A (zh) | 2008-07-18 | 2011-07-13 | 法弗根股份有限公司 | 治疗超重或肥胖受试者的方法 |
EP2350012B1 (en) | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
EP2358203A4 (en) | 2008-10-24 | 2012-06-06 | Univ Wake Forest | ANTICANCER COMPOUNDS BASED ON PLATINUM AND ACRIDINE AND METHODS OF USING SAME |
US20120010259A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
WO2010065879A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
US20130023513A1 (en) | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
US20130210821A1 (en) | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
BR112013001613A2 (pt) * | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
JP5913333B2 (ja) | 2010-10-12 | 2016-04-27 | ザフゲン,インコーポレイテッド | スルホンアミド化合物、およびそれを製造し使用する方法 |
MY177039A (en) | 2010-11-09 | 2020-09-03 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
US20140073691A1 (en) | 2010-11-10 | 2014-03-13 | Zafgen, Inc. | Methods and composition for Treating Thyroid Hormone Related Disorders |
WO2012075026A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of treating obesity using an effective dose of a metap-2 inhibitor |
WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
KR20140006888A (ko) | 2011-01-26 | 2014-01-16 | 자프겐 인크. | 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법 |
CA2835195A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
BR112013028534A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos |
JP6035327B2 (ja) | 2011-05-06 | 2016-11-30 | ザフゲン,インコーポレイテッド | 三環式ピラゾールスルホンアミド化合物ならびにその製造および使用方法 |
US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
KR20140112565A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
CA2861381A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
-
2012
- 2012-05-07 JP JP2014509512A patent/JP6035327B2/ja not_active Expired - Fee Related
- 2012-05-07 EP EP12721140.7A patent/EP2705035B1/en active Active
- 2012-05-07 MX MX2013012923A patent/MX343688B/es active IP Right Grant
- 2012-05-07 WO PCT/US2012/036793 patent/WO2012154679A1/en active Application Filing
- 2012-05-07 BR BR112013028666A patent/BR112013028666A2/pt active Search and Examination
- 2012-05-07 CA CA2835209A patent/CA2835209A1/en not_active Abandoned
- 2012-05-07 KR KR1020137032333A patent/KR20140040739A/ko not_active Application Discontinuation
- 2012-05-07 CN CN201280033357.9A patent/CN103764652B/zh not_active Expired - Fee Related
- 2012-05-07 US US14/116,029 patent/US9242997B2/en not_active Expired - Fee Related
- 2012-05-07 AU AU2012253760A patent/AU2012253760B2/en not_active Ceased
-
2015
- 2015-12-14 US US14/968,013 patent/US20160324865A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2012154679A8 (en) | 2013-11-14 |
US9242997B2 (en) | 2016-01-26 |
MX2013012923A (es) | 2014-02-27 |
AU2012253760A1 (en) | 2013-11-21 |
BR112013028666A2 (pt) | 2017-08-08 |
CN103764652A (zh) | 2014-04-30 |
EP2705035A1 (en) | 2014-03-12 |
US20140080822A1 (en) | 2014-03-20 |
US20160324865A1 (en) | 2016-11-10 |
JP6035327B2 (ja) | 2016-11-30 |
EP2705035B1 (en) | 2016-12-14 |
WO2012154679A1 (en) | 2012-11-15 |
CN103764652B (zh) | 2016-03-23 |
JP2014513140A (ja) | 2014-05-29 |
KR20140040739A (ko) | 2014-04-03 |
AU2012253760B2 (en) | 2016-02-04 |
CA2835209A1 (en) | 2012-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
MX345535B (es) | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. | |
MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
MX339201B (es) | Compuestos de sulfonamida y métodos para elaborarlos y usarlos. | |
MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
BR112013001613A2 (pt) | compostos tricíclicos e métodos para fazer e usar os mesmos. | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
MX343706B (es) | Derivados heterocíclicos novedosos. | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
GB201118656D0 (en) | New compounds | |
TN2012000533A1 (en) | New forms of rifaximin and uses thereof | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
MX2015014083A (es) | Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). | |
PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |